The Form 4 filing, a report of insider stock activity, was filed on November 12, 2026. It lists sales on November 11, 2026, by Gabriel M.I. Mecklenburg, Hinge Health's executive chairman, co-founder and director.
Transaction details
| Transaction | |
|---|---|
| Date of Earliest Transaction | 2026-11-11 |
| Date of Latest Transaction | 2026-11-11 |
| Buy/Sell | sell |
| Transaction Count | 5 |
| Shares Transacted | 200,000 |
| Price | $122.41 |
| Total Transaction Value | $24,482,096.64 |
| Insider | |
| Ticker Symbol | HNGE |
| Company | Hinge Health, Inc. |
| Insider Name | Mecklenburg Gabriel M.I. |
| Insider Title | Director, Other, Exec. Chairman & Co-Founder |
| Sector - Industry | Healthcare - Health Information Services |
| Holdings | |
| Total Shares Owned After Transaction | 0 |
| Position Size Change | 100.00% |
| Filing | |
| Filing Date | 2026-11-12 |
| SEC Link | View filing |
FAQ
What type of transaction is this?
These were sales of Hinge Health (HNGE) shares, reported with transaction code S. The five transactions involve one insider and appear in one filing.
What was the average price of the transaction?
The average price was $122.41 per share across the five sales. This average covers all 200,000 shares; individual sale prices were not available.
How did this transaction affect the insider's holdings?
The insider sold 200,000 shares and reported zero shares owned afterward. The sales covered 100.00% of the shares counted before the trades. The available details do not establish whether that balance included all accounts or types of stock.
What's the total transaction value?
The total value was $24,482,096.64 for all five sales. That figure is rounded to cents from $24,482,096.6411.
Are there any special circumstances around this transaction?
The filing information points to a Rule 10b5-1 trading plan. These plans set trading instructions in advance. Footnote text was not available for this report, so it is unclear which sales the plan covered. Its start date and trading schedule are also unknown.
For research purposes only; not investment advice.